Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2′deoxyribose (IPdR) × 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization

Timothy J. Kinsella; Michael T. Kinsella; Seongwon Hong; Jerry P. Johnson; Brian Burback; Patricia J. Tosca

首页> 外文期刊>Cancer Chemotherapy and Pharmacology >Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2′deoxyribose (IPdR) × 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization

【24h】

Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2′deoxyribose (IPdR) × 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization

机译：在Fischer-344大鼠中口服5-碘-2-嘧啶酮-2'脱氧核糖（IPdR）×28天的毒理学和药代动力学研究：对IPdR介导的放射增敏的初始临床I期试验设计的影响

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

A toxicology and pharmacokinetic study of orally administered (po) IPdR (5-3iodo-2-pyrimidinone-2′deoxyribose, NSC-726188) was performed in Fischer-344 rats using a once daily (qd) × 28 days dosing schedule as proposed for an initial phase I clinical trial of IPdR as a radiosensitizer.

机译：在Fischer-344大鼠中进行了口服（po）IPdR（5-3碘-2-嘧啶酮-2'脱氧核糖，NSC-726188）的毒理学和药代动力学研究，建议的每日一次（qd）×28天给药方案用于IPdR作为放射增敏剂的第一阶段临床试验。

著录项

来源
《Cancer Chemotherapy and Pharmacology》 |2008年第2期|323-334|共12页
作者
Timothy J. Kinsella; Michael T. Kinsella; Seongwon Hong; Jerry P. Johnson; Brian Burback; Patricia J. Tosca;
展开▼
作者单位

Department of Radiation Oncology University Hospitals of Cleveland/Case Comprehensive Cancer Center Cleveland OH USA;

Department of Radiation Oncology University Hospitals of Cleveland/Case Comprehensive Cancer Center Cleveland OH USA;

Chemistry Technical Center Battelle Memorial Institute Columbus OH USA;

Chemistry Technical Center Battelle Memorial Institute Columbus OH USA;

Chemistry Technical Center Battelle Memorial Institute Columbus OH USA;

Chemistry Technical Center Battelle Memorial Institute Columbus OH USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
IPdR; Radiosensitization; PK; Toxicology;

机译：IPdR;放射增敏;PK;毒理学;

相似文献

外文文献
中文文献

1. Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2'deoxyribose (IPdR) x 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization. [J] . Kinsella TJ, Kinsella MT, Hong S, Cancer chemotherapy and pharmacology. . 2008,第2期

机译：在Fischer-344大鼠中口服施用5-碘-2-嘧啶酮-2'脱氧核糖（IPdR）x 28天的毒理学和药代动力学研究：对IPdR介导的放射增敏的初始临床I期试验设计的影响。
2. A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours. [J] . Dumez H, Awada A, Piccart M, Annals of oncology: official journal of the European Society for Medical Oncology . 2006,第7期

机译：晚期实体瘤患者每3周给予伊立替康口服制剂（CPT-11）的I期剂量寻找临床药代动力学研究，每3周给药一次。
3. A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours [J] . H. Dumez, A. Awada, M. Piccart, Annals of Oncology . 2006,第7期

机译：晚期实体瘤患者每3周给予伊立替康口服制剂（CPT-11）的I期剂量寻找临床药代动力学研究，每3周一次
4. First-in-Human Phase 0 Trial of Oral 5-iodo-2-pyrimidinone-2′-deoxyribose (IPdR) in Patients with Advanced Malignancies [O] . Shivaani Kummar, Larry Anderson, Kimberly Hill, -1

机译：先进恶性肿瘤患者的口腔5-Iodo-2-嘧啶酮-2-脱氧（IPDR）的第一阶段0试验
5. Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors [O] . Alain C. Mita, Lisa A. Hammond, Peter L. Bonate, 2006

机译：盐酸三胞苷（ILX651），第三代偶像酰-15的阶段I和药代动力学研究，每28天每28天施用3周，治疗晚期实体肿瘤
6. Initial Submission: 28-day Oral Toxicity Study in Rats Administered Developmental Anionic/nonionic Dan 100 (final Report) with Cover Sheet and Letter dated (sanitized). [R] . 1992

机译：初步提交：28天口服毒性研究大鼠管理发育阴离子/非离子丹100（最终报告）与封面和日期（消毒）。

Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2′deoxyribose (IPdR) × 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization

摘要

著录项

相似文献

相关主题

期刊订阅